Crossmark

Integrative multi-omics identifies AP-1 transcription factor as a targetable mediator of acquired osimertinib resistance in non-small cell lung cancer

Crossref DOI link: https://doi.org/10.1038/s41419-025-07711-z

Published Online: 2025-05-25

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Dayanc, Bengisu

Eris, Sude https://orcid.org/0000-0002-2310-8829
Gulfirat, Nazife Ege https://orcid.org/0009-0000-4716-609X
Ozden-Yilmaz, Gulden

Cakiroglu, Ece

Coskun Deniz, Ozlem Silan

Karakülah, Gökhan https://orcid.org/0000-0001-6706-1375
Erkek-Ozhan, Serap

Senturk, Serif https://orcid.org/0000-0003-3963-2294
Funding

Funding for this research was provided by:

Türkiye Bilimsel ve Teknolojik Araştirma Kurumu (119Z540, 122Z890)
License Information

Text and Data Mining valid from 2025-05-25

Version of Record valid from 2025-05-25
More Information

Article History

Received: 5 February 2025

Revised: 18 April 2025

Accepted: 1 May 2025

First Online: 25 May 2025

Competing interests

: The authors declare no competing interests.

: All methods were performed in accordance with the relevant guidelines and regulations.

Document is current

Any future updates will be listed below